宫颈癌疫苗希瑞适在中国内地上市

The first imported batch of Cervarix, the cervical cancer vaccine, has passed quality inspections and is heading to health clinics across the Chinese mainland, pharmaceutical company GlaxoSmithKline (GSK) said recently.

制药企业葛兰素史克日前表示，中国内地进口的首批宫颈癌疫苗希瑞适已通过质检，正运往各地的卫生诊所。

Cervarix was approved by the China Food and Drug Administration in July last year.

希瑞适是在去年7月获得的国家食品药品监管总局的批准。

The vaccine is registered in 132 countries and regions, and more than 69m doses have been provided to the global market, according to GSK.

据葛兰素史克介绍，该公司已在132个国家及地区对希瑞适进行了注册，并已向全球市场供应超过6900万剂该疫苗。

"Cervical cancer is the third most common cancer among Chinese women aged 15 to 44. There are 100,000 new cases of cervical cancer in China each year, and 30,000 deaths due to the disease," said Qiao Youlin, a top epidemiologist.

著名流行病学家乔友林称：“宫颈癌是我国15岁至44岁女性中第三大高发癌症，全国每年新发病例10万，死亡病例3万。”

"For this reason, cervical cancer vaccination, together with cervical cancer screening, will significantly reduce the incidence of cervical cancer and precancerous lesions," he said.

他说道：“因此，在开展宫颈癌筛查的同时，宫颈癌疫苗接种将显著降低宫颈癌及其癌前病变的发病率。”